Erasca (ERAS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
28 Apr, 2026Executive summary
The annual meeting will be held virtually on June 26, 2026, with voting available online, by phone, or by mail for shareholders of record as of April 27, 2026.
Shareholders will vote on electing three Class II directors, ratifying the appointment of KPMG LLP as independent auditor for 2026, and any other business that may arise.
The company emphasizes electronic delivery of proxy materials to reduce costs and environmental impact.
Voting matters and shareholder proposals
Proposal 1: Elect Alexander W. Casdin, Julie Hambleton, M.D., and Michael D. Varney, Ph.D. as Class II directors for a three-year term expiring at the 2029 annual meeting.
Proposal 2: Ratify KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Shareholders may submit proposals for the 2027 annual meeting by January 15, 2027, and must comply with SEC and bylaw requirements.
Board of directors and corporate governance
The board consists of eight members, with a majority deemed independent under Nasdaq rules.
The board is divided into three classes with staggered three-year terms; directors may only be removed for cause by a two-thirds shareholder vote.
The board has Audit, Compensation, and Nominating and Corporate Governance Committees, all composed of independent directors.
The Lead Independent Director role was established for enhanced oversight, currently held by Dr. Bristol.
The board conducts periodic self-evaluations and encourages director attendance at annual meetings.
Latest events from Erasca
- Virtual meeting to elect directors and ratify auditor, with board support for all proposals.ERAS
Proxy filing28 Apr 2026 - ERAS-0015 shows high response rates and favorable safety in RAS-mutated solid tumors.ERAS
Study result28 Apr 2026 - Advancing best-in-class RAS/MAPK inhibitors with strong data and major milestones ahead.ERAS
Corporate presentation22 Apr 2026 - Clinical advances and robust financing position support long-term RAS therapy development.ERAS
Q4 202512 Mar 2026 - Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024.ERAS
Oppenheimer 36th Annual Healthcare Life Sciences Conference26 Feb 2026 - Early clinical data show promising efficacy and safety for next-generation pan-RAS and pan-KRAS inhibitors.ERAS
Guggenheim Securities Emerging Outlook: Biotech Summit 202612 Feb 2026 - Advancing innovative RAS/MAPK-targeted therapies with strong financial backing and pivotal trials.ERAS
2024 Cantor Fitzgerald Global Healthcare Conference3 Feb 2026 - Refocused RAS/MAPK pipeline, strong clinical progress, and cash runway support key milestones to 2027.ERAS
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Advancing RAS-targeted therapies with pivotal trials and strong preclinical results.ERAS
Jefferies 2024 Global Healthcare Conference1 Feb 2026